156 related articles for article (PubMed ID: 10572842)
1. What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?
Leal P; Stein K; Rosenberg W
J Med Screen; 1999; 6(3):124-31. PubMed ID: 10572842
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
3. Screening for Hepatitis C in injecting drug users: a cost utility analysis.
Stein K; Dalziel K; Walker A; Jenkins B; Round A; Royle P
J Public Health (Oxf); 2004 Mar; 26(1):61-71. PubMed ID: 15044577
[TBL] [Abstract][Full Text] [Related]
4. Case finding for hepatitis C in primary care: a cost utility analysis.
Thompson Coon J; Castelnuovo E; Pitt M; Cramp M; Siebert U; Stein K
Fam Pract; 2006 Aug; 23(4):393-406. PubMed ID: 16799165
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
[TBL] [Abstract][Full Text] [Related]
8. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
9. Economic model of a birth cohort screening program for hepatitis C virus.
McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
11. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
Annemans L; Warie H; Nechelput M; Peraux B
Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.
John-Baptiste A; Yeung MW; Leung V; van der Velde G; Krahn M
Pharmacoeconomics; 2012 Nov; 30(11):1015-34. PubMed ID: 23050771
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
[TBL] [Abstract][Full Text] [Related]
16. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors.
Hladik W; Kataaha P; Mermin J; Purdy M; Otekat G; Lackritz E; Alter MJ; Downing R
Trop Med Int Health; 2006 Jun; 11(6):951-4. PubMed ID: 16772018
[TBL] [Abstract][Full Text] [Related]
18. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C screening strategies in hemodialysis patients.
Saab S; Brezina M; Gitnick G; Martin P; Yee HF
Am J Kidney Dis; 2001 Jul; 38(1):91-7. PubMed ID: 11431187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]